ARCHIVES

FDA Authority To Regulate Off-Label Promotion Challenged In Federal Court.

This article is from The Cancer Letter archive.

Vol. 36 No. 01 | January 15, 2010

Download PDF Visit The Full Archive

Related Articles

Long-Term Results Of STAR Find Raloxifene Causes Fewer, Less Severe Side Effects

April 30, 2010

NCI Plans 3 Percent Across-The-Board Cut To Pool Funds For High Priorities In FY08.

September 21, 2007

Markup Of Cancer Act Renewal Set For Mid-October

September 21, 1979

Women Surgeons: We Need Answers On Tamoxifin Now

May 13, 1994

Shingleton To Retire As Director Of Duke Comprehensive Center

July 10, 1981

NCI Projects Only 25% Of R01s Will Be Funded In FY89

November 25, 1988